It is suggested that channel activation with TRPM8 agonist in nanocarriers could be used in the early stages of prostate cancer to decrease tumor cell dissemination (Grolez et al., 2019b; Grolez et al., 2022). This evidence concerns the gene TRPM8 and prostate cancer.